Using ELISA to quantify the levels of LCN2, they showed that the median level of this biomarker in the synovial fluid collected from patients diagnosed with PJI was 135 times higher than that in the aseptic failure group. This evidence concerns the gene LCN2 and juvenile polyposis syndrome.